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Introduction: Epidermal growth factor receptor (EGFR) mutations are
strong determinants of tumor response to EGFR tyrosine kinase inhib-
itors in non-small cell lung cancers (NSCLCs). Currently available
methods of EGFR mutation detection rely on direct sequencing. Here,
we describe the use of an alternative way to screen EGFR mutations.
Methods: A total of 109 frozen tumor specimens from NSCLC
patients were obtained. For mutational analysis of EGFR exons 18,
19, and 21, reverse transcription-polymerase chain reaction was
performed on the cDNA using original primers designed for restric-
tion fragment length polymorphism (RFLP).
Results: EGFR mutations were detected in 37 patients (34%) by both
RFLP and direct sequencing except one case in which it was detected
only by RFLP. EGFR mutations were more frequently observed to be
significant by multivariate analysis in patients with adenocarcinoma
(OR  5.56), no-smoking history (OR  4.34), and 65-year-old or
younger (OR  2.64), but not in women (OR  1.14). Among 37
patients, 18 were treated with gefitinib and 9 responded to the treatment.
One patient without any mutation responded.
Conclusion: RFLP is a useful method for screening EGFR muta-
tions and can also be applied to predicting the sensitivity of NSCLC
patients to EGFR-tyrosine kinase inhibitors.
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Lung cancer is the most common cause of death in bothmen and women worldwide, with non-small cell lung
cancer (NSCLC) accounting for approximately 80% of these
cases.1 Recently, two drugs, gefitinib (Iressa) and elrotinib
(Tarceva), which target the epidermal growth factor receptor
(EGFR) tyrosine kinase (TK), were approved in different
countries to treat NSCLC.2,3
In 2004, three separate studies reported that muta-
tions in the EGFR gene in lung carcinomas made the
disease more responsive to treatment with TK inhibi-
tors.4–6 Since then, a multitude of data has emerged from
different groups around the world.
Most EGFR somatic mutations were exclusively de-
tected in adenocarcinomas, including bronchiolo-alveolar
carcinomas. The mutations were detected in exons 18, 19,
and 21, which encode the intracellular kinase domain. The
mutations detected in exon 18 had substitution of the amino
acid G719 in the P-loop, whereas those detected in exon 21
had substitution of an amino acid in the activation domain
(L858 and L861). The mutations in exon 19 were in-frame
deletions that may alter the structure of C helices. All of the
EGFR mutations affect amino acids near the ATP-binding
pocket that is targeted by gefitinib. Functional assays re-
vealed that the hotspot mutants of EGFR had a higher
EGF-independent activation than did the wild-type EGFR.4–7
EGFR mutations are predominantly found in Asians,
women, adenocarcinomas, and never-smokers, which ex-
plains the association between the clinical predictors and
gefitinib sensitivity.4–6,8–10
Direct gene sequencing is a standard method for de-
tecting gene mutations. However, it is not suitable for clinical
pretherapeutic screening of patients because it is time-con-
suming, costly, and sometimes unreliable. Thus, an easy and
reliable method for detecting EGFR mutations that can be
used clinically is needed.
The aim of this study was to establish an easy and
reliable method with which to screen EGFR mutations. We
studied a large series of consecutive NSCLC patients for
EGFR mutations in exons 18, 19, and 21 using a comparative
approach between 2 techniques: direct sequencing of poly-
merase chain reaction (PCR) products and restriction frag-
ment length polymorphism (RFLP) analysis.
PATIENTS AND METHODS
Cell Lines and Plasmids Containing Wild-Type
and Mutant EGFR Genes
Three NSCLC cell lines, SK-MES-1, H1650, and
H1975, were purchased from American Type Culture Col-
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lection (Manassas, VA). SK-MES-1 has wild-type EGFR.
H1650 contains an E746-A750 deletion mutation in exon 19.
H1975 contains an L858R point mutation in exon 21 and a
secondary T790M point mutation which is related to the
resistance to gefitinib and erlotinib in exon 20.11,12 pL420
plasmids containing wild-type, G719C and L858R mutant
EGFR genes (generous gifts from Dr. Matthew Myerson,
Dana-Farber Cancer Institute, Boston) were used to validate
the RFLP assay for corresponding point mutations in exon 18
and exon 21, respectively.
Extraction of Nucleic Acids and Restriction
Fragment Length Polymorphism for EGFR
Mutants
Genomic DNA was isolated from tumors and lung
cancer cell lines using the DNeasy Mini Kit (Qiagen, Munich,
Germany), according to the manufacturer’s protocol. Total
RNA was also isolated from the same samples using the
RNeasy Mini Kit (Qiagen) and cDNA was synthesized using
an Omniscript Reverse Transcription kit (Qiagen).
We have designed original primers against cDNA for
RFLP to detect mutations (Figure 1). The following primers
containing appended M13 forward or reverse primer tails for
direct sequencing were used for PCR amplification: exon 18
(forward, 5-TGTAAAACGACGGCCAGTCCCTGGGGATC-
GGCCTCTTCATGCGA-3; reverse, 5-CAGGAAACAGCT-
ATGACCTATACACCGTGCCGAACGCACCGGGG-3),
exon 19 (forward, 5-TGTAAAACGACGGCCAGTGATCA-
AAGTGCTGGGCTCC-3; reverse, 5-CAGGAAACAGCT-
ATGACCACGGTGGAGGTGAGGCAGAT-3), exon 21
(forward, 5-TGTAAAACGACGGCCAGTAACACCGCA-
GCATGTCAAGAT-3; reverse, 5-CAGGAAACAGCTA-
TGACCATTCCAATGCCATCCACTTGAT-3), exon 20
(forward, 5-TGTAAAACGACGGCCAGTCCTCGATGA-
AGCCTACGTGATG-3; reverse, 5-CAGGAAACAGCTA-
TGACCGGCAGCCGAAGGGTATGAGCTG-3). The PCR
reaction was performed on 1 L of template cDNA, as
prepared above, to which were added 10 buffer (10 mM
Tris–HCl, pH 8.3, 50 mM KCl and 1.5 mM MgCl2), 0.2
mM of both dNTP and 0.25 U AmpliTaq Gold, and 0.2 M
forward and reverse primers in a 50 L reaction volume.
The “hot start” PCR cycling parameters were: one cycle of
95°C for 15 minutes, 40 cycles of 95°C for 20 seconds, 60°C
for 30 seconds, and 72°C for 1 minute, followed by one cycle
of 72°C for 3 minutes.
On the other hand, for the additional experiment to
compare the sensitivity of the assay between cDNA and
genomic DNA, we also performed RFLP against genomic
DNA for exon 19 and exon 21. We chose external and nested
primers designed by Paez JG5 for PCR on genomic DNA. We
use the following primers in external PCR: Exon 19,
(forward, 5-AAATAATCAGTGTGATTCGTGGAG-3;
reverse, 5-GAGGCCAGTGCTGTCTCTAAGG-3), Exon
21, (forward, 5-GCAGCGGGTTACATCTTCTTTC-3; re-
verse, 5-CAGCTCTGGCTCACACTACCAG-3). And we
used in nested PCR: Exon 19, (forward, 5-GTGCATCGCT-
GGTAACATCC-3; reverse, 5-TGTGGAGATGAGCAG-
GGTCT-3), Exon 21, (forward, 5-GCTCAGAGCCTGG-
CATGAA-3; reverse, 5-CATCCTCCCCTGCATGTGT-3).
External-round PCR reaction was performed on 0.1 g of
genomic DNA with the same protocol as described above.
For nested-round PCR reaction, 3 L of the external-round
PCR product was amplified in a second 50 L reaction
mixture using nested primers assembled as external-round
PCR reaction, described above.
Mutation Assay for G719X in Exon 18
The restriction enzyme ApaI digests the GGGCCC
sequence in the amplicon of the wild-type allele. In contrast,
the mutant allele was not digested because of the base
substitution of G to X at the second base of GGGCCC. The
PCR products after digestion were run on 2% agarose gel and
the existence of the mutation was assessed (Figure 1).
Mutation Assay for Deletion in Exon 19
Because the range of exon 19 deletions containing
commonly deleted codons 746 to 751 was reported to be from
9 to 18 bp, differences in the sizes of the PCR products
enabled us to distinguish mutant from wild-type. The PCR
products were run on 2% agarose gel and the existence of
exon 19 mutations was assessed (Figure 1).
Mutation Assay for L858R and L861Q in
Exon 21
The restriction enzyme MscI was used to digest the
TGGCCA sequence in the amplicon of the wild-type allele.
In contrast, mutant type (L858R) was not digested because of
the base substitution of T to G at the first base of TGGCCA.
On the other hand, 2582TG mutation creates a new PvuII
restriction site, CAGCTG, that can be used for a PCR-RFLP
assay to distinguish L861Q mutant allele from wild-type. The
PCR products were digested simultaneously with the restric-
tion enzymes MscI and PvuII and run on 2% agarose gel, and
the existence of these mutations was assessed (Figure 1).
FIGURE 1. Scheme of digestion of PCR products and gel
electrophoresis. PCR products were digested with corre-
sponding enzymes (without digestion for exon 19), then
were run on 2% agarose gel and the existence of mutations
was assessed. Both ApaI and MscI digest wild type EGFR al-
lele, while PvuII digests mutant EGFR allele.
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Mutation Assay for T790M in Exon 20
The restriction enzyme NlaIII was used to digest the
CATG sequence in the amplicon of the mutant type (T790M)
allele because of the base substitution of C to T at the third
base of CACG. In contrast, wild-type allele was not digested.
The PCR products after digestion were run on 2% agarose gel
and the existence of the mutation was assessed (Figure 1).
EGFR Gene Sequencing
EGFR gene mutations in the cDNA samples were
examined using PCR-based direct sequencing for exons 18,
19, and 21 to confirm the results of RFLP analysis. Sequenc-
ing was performed using the Applied Biosystems PRISM dye
terminator cycle sequencing method with an ABI PRISM
3100 Genetic Analyzer (Perkin-Elmer Corp., Foster City,
CA) at the Central Research Center of Keio University
Hospital.
Patients and Clinical Samples
Tumor samples from 109 patients diagnosed as having
primary NSCLC by histopathological examination were ob-
tained from Keio University (82 samples) and Kawasaki
Municipal Hospital (27 samples). Ninety-one frozen tumor
specimens were obtained either by surgery (n  48), com-
puted tomography-guided needle lung biopsy (n  32) or
ultrasonography-guided needle lung biopsy (n 5), or TBLB
(n  6). Fourteen samples from pleural effusion, three sam-
ples from pericardial effusion, and one sputum sample were
also obtained. Malignant effusion collected by pleurocentesis
or cardiocentesis was centrifuged and the cell pellet was
collected after removal of the supernatant. All samples were
stored at 80°C until the DNA and RNA extraction proce-
dures described above were performed.
All patient samples were collected or tested with in-
formed consent, as approved by our respective institutional
review boards. Clinical parameters for the patients were
obtained from their medical records.
Clinical information was available for all 109 patients
and Table 1 summarizes the demographic and clinical data of
the study cohorts.
Statistical Analyses
The association between EGFR mutational status and
tumor response to gefitinib was assessed using the 2 test.
Multivariate analysis using logistic regression models was
performed to assess the associations among histologic sub-
types, gender, smoking history, age, and mutational status.
All analyses were performed using Stat View (version 5, SAS
Institute Inc., Cary, NC) software on a Macintosh computer.
RESULTS
Patterns of PCR-RFLP for EGFR Mutations on
Gel-Electrophoresis
Figure 1 presents the predicted gel-electrophoresis
patterns for PCR-RFLP samples. We first confirmed the
patterns of electrophoresis for EGFR mutations using vec-
tors containing an EGFR exon 18 or 21 point mutation as
well as wild-type or cell lines containing an exon 19
deletion mutation and wild-type genes. G719S and L858R
mutant vectors were clearly distinguished from wild-type
by PCR-RFLP (Figure 2A and Figure 2C, respectively). On
the other hand, a shorter band from the deleted allele in
exon 19 and a longer band from the wild-type allele were
observed by reverse transcription-polymerase chain reac-
tion from H1650 (Figure 2B).
Sensitivity of PCR-RFLP Analysis of EGFR
Mutations in Exon 19 and Exon 21
We evaluated the sensitivity of our RFLP assay in exon
19 or in exon 21 by combining SK-MES-1 cells with H1975
or H1650, respectively, in different ratios (Figure 3A). In
exon 19, a shorter band from the deleted allele was detected
up to the level of 1  102-fold dilution. In exon 21, the
mutant allele at the 154 bp band was also detected up to the
level of 1  102-fold dilution. The band of 154 bp indicates
digested mutant alleles, and the band of 98 bp indicates
wild-type alleles.
TABLE 1. Clinicopathological Features of All Patients
Variables Subset No. (%)
No. patients 109
Age (yr) Mean 64.9
Range 30–85
Sex Male 59 (54.1)
Female 50 (45.9)
Stage I 18 (16.5)
II 7 (6.4)
III 33 (30.3)
IV 51 (46.8)
Smoking history Never smoker 37 (34.0)
Ever-smoker 72 (66.0)
Tumor type Adenocarcinoma 79 (72.6)
AWBF 1 (0.9)
BAC 5 (4.6)
Squamous cell carcinoma 13 (11.9)
Large cell carcinoma 1 (0.9)
LCNEC 1 (0.9)
Adenosquamous carcinoma 1 (0.9)
Pleomorphic 2 (1.8)
Others 5 (5.5)
Tumor samples Resected tumor 48 (44.0)
CT-guided lung biopsy 32 (29.4)
US-guided lung biopsy 5 (4.6)
TBLB 6 (5.5)
Pleural fluid 14 (12.8)
Pericardial fluid 3 (2.8)
Sputum 1 (0.9)
EGFR mutations 37 (33.9)
Exon 18 1/37, 2.7%
Exon 19 22 22/37, 59.5%
Exon 21 14 14/37, 37.8%
AWBF, adenocarcinoma with bronchiolo-alveolar carcinoma features; BAC, bron-
chiolo-alveolar carcinoma; EGFR, epidermal growth factor receptor; LCNEC, large cell
neuroendocrine carcinoma; TBLB, transbronchial lung biopsy.
Kawada et al. Journal of Thoracic Oncology • Volume 3, Number 10, October 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1098
We also compared the sensitivity of cDNA and
genomic DNA samples in pleural effusion from NSCLC
patients for RFLP assay.
As malignant pleural effusion usually contains many
hematopoietic cells such as macrophages and lymphocytes
in addition to tumor cells, as a consequence, dilution of
FIGURE 3. Sensitivity of PCR-RFLP analysis of EGFR mutations. A, In exon 19, H1650 was mixed with SK-MES-1 from 1- to 103-
fold. A shorter band from the deleted allele was detected up to the level of 1  102-fold dilution. In exon 21, H1975 was mixed
with SK-MES-1 from 1- to 103-fold. The mutant allele at the 154 bp band was detected up to the level of 1  102-fold dilution.
SK-MES-1, lung cancer cell line without EGFR mutation; H1650, lung cancer cell line with EGFR mutation (del E746-A750); H1975,
lung cancer cell line with EGFR mutation (L858R). B, PCR-RFLP was performed using either cDNA or genomic DNA (gDNA). The
mutant allele in exon 19 was only detected by using cDNA in the case of malignant pleural effusion. In exon 21, the mutant allele
(a 154 bp digested fragment) can be distinguished readily by using cDNA in the case of malignant pleural effusion of NSCLC.
H1650; lung cancer cell line with EGFR mutation (del E746-A750), H1975; lung cancer cell line with EGFR mutation (L858R),
SK-MES-1; lung cancer cell line without EGFR mutation, P; the case of malignant pleural effusion of NSCLC, M; marker.
FIGURE 2. Demographic data of
EGFR mutations in exon 18, 19, 21,
and 20 by PCR-RFLP. A, The PCR prod-
ucts of exon18 treated with ApaI. B,
The PCR products of exon19. C, The
PCR products of the exon21 treated
with MscI and PvuII, simultaneously. D,
The PCR products of exon20 treated
with NlaIII. WT, EGFR (wild type) vec-
tor; A4, EGFR (G719S) vector; H1650,
lung cancer cell line with EGFR muta-
tion (del E746-A750); A1, EGFR (L858R)
vector; H1975, lung cancer cell line
with EGFR mutation (L858R and
T790M); SK-MES-1, lung cancer cell
line without EGFR mutation.
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genomic DNA derived from tumor cells occurs. To mini-
mize the dilution caused by contaminated hematopoietic or
other nontumor cells, we have chosen cDNA instead of
genomic DNA for PCR/RFLP, taking into consideration
that hematopoietic cells usually do not express the EGFR
gene. Indeed, we could detect the mutation bands only
when cDNA was used but not when genomic DNA was
used from NSCLC patients with malignant pleural effusion
(Figure 3B).
Results of PCR-RFLP Analysis of EGFR
Mutations in Exons 18, 19, 21, and 20 in
Clinical Samples
Only 1 patient (patient 56) showed 2 fragments (237 bp
and 195 bp, corresponding to mutant and wild-type alleles,
respectively) by RFLP using ApaI for exon 18 (Figure 4A).
We found a novel point mutation in codon 719 (2146GC
[G719D]) confirmed by direct sequencing.
In exon 19, we found 22 deletion mutations. Patients who
had a deletion mutation showed two fragments corresponding to
wild-type and deletion mutant alleles (Figure 4B).
In exon 21 using MscI and PvuII, we found 14 point
mutations in codon 858 by RFLP. Patients who had a
2573TG point mutation showed 3 fragments (154 bp and 98
bp, corresponding to L858R mutant and wild-type alleles,
respectively) (Figure 4C). No L861Q mutation was observed
in our specimens.
In exon 20 using NlaIII, we found 2 point mutations in
codon 790 (2369CT [T790M]) by RFLP. Patients who had
a 2369CT point mutation showed 2 fragments (154 bp, 114
bp, and 40 bp, corresponding to T790M mutant and wild-type
alleles, respectively) (Figure 4D).
Finally, we found 37 EGFR mutations (34%) in exons
18, 19, and 21 in the present study.
EGFR Mutations and Clinicopathologic
Features
(Table 2) The mutation status was significantly corre-
lated with pathologic subtype (adenocarcinoma including
bronchiolo-alveolar carcinomas versus nonadenocarcinoma,
odds ratio  5.56, p  0.035), smoking status (never-
smokers versus ever-smokers; odds ratio  4.34, p  0.007)
and age (65-year-old or younger versus older than 65 years;
odds ratio  2.64, p  0.037) but not with gender (female
versus male; odds ratio  1.14, p  0.813) by logistic
multivariate analysis.
Indeed the female never-smoker patients with adeno-
carcinoma had a high mutation rate (18/27, 66.6%), whereas
the young never-smokers with adenocarcinoma had a higher
mutation rate (13/15, 86.7%). Moreover, the young female
never-smoker patients with adenocarcinoma had the highest
mutation rate (10/11, 90.9%), whereas the elderly male ever-
smokers with nonadenocarcinoma had the lowest mutation
rate (1/11, 9.1%).
EGFR mutations were not influenced by disease extent
(TNM stage) (data not shown).
EGFR Mutations and Clinical Outcome in
Patients Treated with Gefitinib
(Table 3) Among 109 patients, 36 were treated with
gefitinib (250 mg/d) and evaluated for their response. Eight of
36 patients were treated with gefitinib as an initial treatment.
The results of the evaluation showed that 10 patients re-
sponded to the treatment. Nine of 10 responsive patients had
mutations in exon 19 or exon 21, whereas one had no
mutations. The response rate to gefitinib in patients with
EGFR deletion mutations in exon 19 and L858R point mu-
tation in exon 21 was 58.3% (7 of 12) and 33.3% (2 of 6, 1
of 7 patients was not evaluable due to discontinuation of
treatment because of side effect), respectively. The patient
FIGURE 4. Result of PCR-RFLP analysis of EGFR
mutations in exon 18, 19, and 21 in clinical sam-
ples. A, In exon 18, only patient 56 showed 2
fragments (237 bp and 195 bp, corresponding
to mutant and wild type alleles, respectively).
Direct sequencing analysis of PCR products is
shown. Point mutation 2156GC (G719D) (ar-
row) is detected in patient 56. B, In exon 19,
patients 11, 28, and 46 showed 2 fragments cor-
responding to wild type and deletion mutant
alleles. In-frame deletion was detected in patients
28. C, In exon 21, patients 3,12, and 41 showed
2 fragments (154 bp and 98 bp, corresponding
to L858R mutant and wild type alleles, respec-
tively). No L861Q mutation was observed in our
specimens. Point mutation 2573TG (L858R)
was detected in patients 3, 12, and 41.
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with G719D mutation in exon 18 was not treated with
gefitinib. On the other hand, 2 patients had T790M mutation
and both also had activating mutations (data not shown). One
patient who had L858R mutation was not treated with ge-
fitinib. Another patient who had deletion mutation in exon 19
was resistant to gefitinib.
EGFR mutations were more frequently observed in
samples from the patients who showed complete or partial
responses (9 of 10 cases, 90.0%) than in samples from
patients with stable disease or progressive disease (9 of 26,
34.6%; p  0.003). Alternatively, the response rate to ge-
fitinib in patients with EGFR mutations was 50% (9 of 18).
Comparison of Detection of Mutations by RFLP
and Direct Sequencing
EGFR mutations were detected in 37 patients. They
were detected by both RFLP and direct sequencing methods
in 36 cases, whereas it was detected only by RFLP but not by
direct sequencing in one case.
DISCUSSION
In the present study, we have described a reliable
PCR-RFLP assay for the detection of mutations occurring
in the EGFR TK domain. We have also analyzed a large
series of NSCLCs for mutations in the TK domain of the
EGFR gene by RFLP to assess the actual incidence of this
genetic abnormality and its distribution according to his-
tologic type, sex, smoking history, age, and TNM system
parameters. In addition, we have analyzed the relationship
between EGFR mutations and clinical outcome in patients
treated with gefitinib.
In our analysis of 109 cases, most of the EGFR
mutations were present in adenocarcinomas. Approxi-
mately 41% of adenocarcinomas showed the EGFR muta-
tion, whereas the corresponding figure was 8% for non-
adenocarcinomas. In univariate analysis, EGFR mutations
were also significantly more frequent in women, younger
patients, and never-smokers (data not shown). However,
when the histotype, sex, smoking history, and age were
tested by multivariate analysis against the presence of
mutations in EGFR as a dependent variable, histotype,
history of never smoking, and younger age (65) re-
mained significant, while female sex did not.
EGFR mutations were more frequently observed in the
samples from younger patients (45.5%) than older patients
(22.2%). Tomizawa et al. also reported that EGFR mutation
was significantly more frequent in younger patients (38%)
than in older patients (12%, p  0.0001).13 For lung cancer,
young adults are generally defined as being 40 or 45 years
and under, whereas elderly patients are defined as 65 or 70
years and older. When we used 45 years as a cutoff value for
age, there was no significant difference between the younger
and the older patients regarding EGFR mutations, either by
univariate or multivariate analysis. On the other hand, when
65-year-old was used as the cutoff value, the younger, non-
elderly patients had a significantly higher prevalence of the
EGFR mutation. Indeed, we found that the nonelderly (65
years) female never-smoking patients with adenocarcinoma
had the highest mutation rate (90.9%), however, this mutation
rate was almost identical to the value found in the nonelderly
never-smokers with adenocarcinoma independent of sex
(86.7%). Moreover, we found only one mutation in the
elderly ever-smoker patients with nonadenocarcinoma (1/16,
6.3%) or in males with the above 3 indexes (9.1%). Together
with the findings of multivariate analysis, the results suggest
that being female may not be a significant independent factor
for predicting EGFR mutations, as has been reported else-
where. This may be partially explained by the fact that female
was the predominant sex in young and adenocarcinoma
patients.14
EGFR mutations were more frequently observed in
samples from patients who showed a complete or partial
response than in samples from patients with a stable or
progressive disease, supporting the findings of many previous
reports (Table 3). The exon 19 deletion mutations are re-
TABLE 2. Correlation of EGFR Mutations with
Clinicopathologic Features
EGFR
Mutation
Odds
Ratio p 
(A) Gender and EGFR
mutation status
0.813
Female 22 28 1.14
Male 15 44
(B) Histology and EGFR
mutation status
0.035
Adenocarcinoma (with BAC) 35 50 5.56
Nonadenocarcinoma 2 22
(C) Smoking habit and EGFR
mutation status
0.007
Never smoker 21 16 4.34
Ever-smoker 16 56
(D) Age and EGFR mutation
status
0.037
65 25 30 2.64
65 12 42
EGFR, epidermal growth factor receptor; BAC, bronchiolo-alveolar carcinoma.
TABLE 3. Response to Gefitinib and EGFR Mutation Status
Response
EGFR Mutation
 
CR 1 0
PR 8 1
SD 5 1
PD 4 16
CR/PR 9 1
SD/PD 9 17 p  0.003
CR/PR/SD 14 2
PD 4 16 p  0.00001
CR, complete response; EGFR, epidermal growth factor receptor; PD, progressive
disease; PR, partial response; SD, stable disease.
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ported to be more predictive of gefitinib response or demo-
graphics compared with the exon 21 mutation.9,15,16 The
response rate in our analysis was also higher in patients with
the exon 19 deletion mutations (58.3%) compared with those
with L858R (33.3%).
In tumors from patients not treated with either gefitinib
or erlotinib, the 2369CT mutation (T790M) seems to be
extremely rare. We have identified only 2 cases of this
mutation in 109 tumors (1.8%).
Large-scale screening requires a rapid and sensitive
technique. At the present time, EGFR mutation detection is
most commonly performed by direct DNA sequencing of the
EGFR kinase domain. However, direct sequencing has sev-
eral disadvantages with regard to clinical use. The most
notable of these is a low detection rate when DNA from
clinical samples is used, presumably because of the presence
of high rates of contaminated normal and fibrous tissues in
tumor samples. Detection of mutations by this method re-
quires at least 30% of the mutated DNA in a sample.17
Some investigators have attempted to improve the sen-
sitivity of detection of EGFR mutations in samples containing
a mixture of tumor and normal cells. Wookey et al. reported
that the ARMS method (Scorpion Amplified Refractory Mu-
tation System technology) was superior to the direct sequenc-
ing method and introduced the WAVE method for detecting
EGFR mutations.18 Moreover, EGFR mutations were detect-
able using the ARMS method in serum DNA from patients
with NSCLC.19 One attempt involved the detection of EGFR
mutations using a LightCycler PCR assay.20 SSCP assay is
more sensitive than direct sequencing and is a more rapid
method.21 Recently, 2 rapid and sensitive methods have
been demonstrated: the peptide nucleic acid-locked nucleic
acid PCR clamp method22 and mutant-enriched PCR as-
say.23 In these studies, EGFR mutations were detected in
the presence of 1000-fold and 2000-fold wild-type EGFR
genes, respectively.
Indeed, some of the above methods seem to be more
sensitive than our method, however, our method does not
require special equipment such as real-time PCR machines
using multiple dyes like in the Scorpion ARMS and peptide
nucleic acid-locked nucleic acid clamp PCR methods. Thus,
compared with the other techniques, ours is relatively simple,
cost-effective, fast, and reliable as we can see the mutated
bands directly. The sensitivity for detection of mutations by
our method is also sufficiently high as it is able to detect
mutations in samples containing as few as 1% mutated cancer
cells (Figure 3A). Although a variety of different mutations
are seen spanning the entire EGFR TK domain, 94% reside in
exons 18 (5%), 19 (48%), and 21 (41%).24 Using the PCR-
RFLP analysis, more than 90% of the mutations in the EGFR
gene can be immediately recognized.
Specimens of lung tumor usually contain substantial
proportions of normal cells, such as fibrous tissue and pe-
ripheral blood cells. Also, normal cells, such as inflammatory
cells or mesothelial cells, are also contained in the pleural
effusion of lung cancer patients, in addition to tumor cells.
Contaminated wild-type DNA interferes with accurate anal-
ysis. Most epithelial cells express EGFR, whereas cells of
hematopoietic origin are usually EGFR-negative.25 Using
cDNA instead of genomic DNA for the PCR-RFLP, we can
minimize the influence of the contaminated hematopoietic or
other nontumor cells, which have no EGFR expression. We
compared the sensitivity of cDNA and genomic DNA sam-
ples in pleural effusion from NSCLC patients when using the
RFLP assay. We were able to detect the mutation bands only
when a cDNA sample was used (Figure 3B). Thus, PCR-
RFLP using cDNA is more sensitive than using DNA, par-
ticularly when analyzing contaminated samples.
In conclusion, mutations in the EGFR TK domain
define a new molecular type of lung carcinoma that is likely
to respond to EGFR TK inhibitors. Good clinical independent
predictive factors are suggested to be a nonsmoking history,
younger age (65), and histotype of adenocarcinoma, but not
female sex. The PCR-RFLP assay described here is a rapid
and reliable method for the screening of EGFR kinase domain
mutations in lung cancer patients with various types of
samples, as we can minimize the influence of contaminating
cells having no EGFR expression using cDNA. The sensitiv-
ity, cost, and simplicity of the procedure are satisfactory for
genetic testing of lung cancer patients at the clinical labora-
tory level. RFLP will be one of the useful assays for predict-
ing the sensitivity of NSCLC patients to EGFR-TKIs.
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